GeoPolitics Pulse

The Heartbeat of World events

Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC

by ·

European Commission approves Mirum’s LIVMARLI for PFIC in young patients, highlighting significant clinical benefits and positive trial results.Read More

Related posts:

  1. Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
  2. Rhythm Pharmaceuticals Announces European Commission Expands IMCIVREE … – Morningstar
  3. Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
  4. Acadia Pharmaceuticals Submits Marketing Authorization Application to the … – Business Wire
  5. Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for …